BD to Invest $35 Million in Nebraska Facility to Expand Prefilled Flush Syringe Manufacturing to Support U.S. Health Care

Rhea-AI Summary

BD (NYSE: BDX) has announced a $35 million investment to expand its prefilled flush syringe manufacturing capacity at its Columbus, Nebraska facility. The expansion will create approximately 50 new jobs and increase production of BD® PosiFlush™ Prefilled Flush Syringes by hundreds of millions of units annually.

The company has already invested over $80 million in the past three years, increasing U.S. production by more than 750 million units, including a 10% increase this year. This investment is part of BD's larger $2.5 billion commitment to enhance U.S. manufacturing capacity over the next five years.

The Columbus facility, operating for over 75 years, is the largest manufacturer of prefilled flush devices in the U.S. BD currently operates more than 30 U.S. manufacturing and distribution facilities across 17 states and Puerto Rico, employing over 10,000 people.

Positive

• Investment of $35 million to expand U.S. manufacturing capacity
• Creation of approximately 50 new jobs in Nebraska
• Production increase of hundreds of millions of additional units annually
• Previous investments led to 750 million unit increase and 10% growth this year
• Part of larger $2.5 billion U.S. manufacturing investment plan

Negative

• None.

News Market Reaction

+1.43%

1 alert

+1.43% News Effect

On the day this news was published, BDX gained 1.43%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

FRANKLIN LAKES, N.J., Aug. 4, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to invest more than $35 million and add approximately 50 new jobs to expand prefilled flush syringe manufacturing at its Columbus, Neb. facility to increase the resiliency of the U.S. health care system.

The investments will support new BD® PosiFlush™ Prefilled Flush Syringe production lines, product innovation and operational efficiencies, enabling BD to produce hundreds of millions of additional units annually to meet growing demand from U.S. hospitals and health systems. 

"BD PosiFlush™ Syringes are essential to everyday patient care for keeping catheters clear and safely delivering medications," said Eric Borin, worldwide president of BD Medication Delivery Solutions. "Our latest investments boost U.S. production capacity and reinforce our commitment to a reliable supply for health care providers and the patients they serve."

Prefilled flush devices like PosiFlush™ Prefilled Flush Syringes are used in nearly every hospital across the country as part of catheter care and maintenance to help prevent catheter-related complications and support efficient, high-quality patient care. Quality in manufacturing is critical as these devices deliver fluid directly into a patient's bloodstream, where any contamination or defect can have serious, even fatal, consequences.

PosiFlush™ Prefilled Flush Syringes are manufactured using a fully automated, hands-free process, ensuring that the first person to touch the syringe is the clinician – helping to reduce the potential for contamination. Every syringe is inspected using a rigorous, multi-step, end-to-end inspection process to meet high quality standards for patients and providers.

Over the past three years, BD has invested more than $80 million to expand BD PosiFlush™ capacity, increasing U.S. production by more than 750 million units, including a 10% increase this year alone. The company's facility in Columbus is the largest manufacturer of prefilled flush devices in the U.S. and has been operating for more than 75 years.

This announcement builds on the company's broader commitment to strengthening U.S. health care infrastructure and ensuring long-term supply resilience. Earlier this year, BD announced its intention to invest $2.5 billion in U.S. manufacturing capacity over the next five years, further strengthening its position as one of the largest U.S. manufacturers of medical devices. This includes more than $40 million in investments across its U.S. manufacturing network to expand capacity for syringes, needles and IV catheters – products essential to everyday clinical care.

BD operates more than 30 U.S. manufacturing and distribution facilities across 17 states and Puerto Rico that employ more than 10,000 people. These facilities form a critical backbone of the U.S. medical device supply chain, helping ensure consistent access to high-quality medical devices nationwide.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

Contacts:
Media:	Investors:
Alyssa Kretlow	Adam Reiffe
BD Public Relations	Sr. Director, Investor Relations
551.238.4391	201.847.6927
alyssa.kretlow@bd.com	adam.reiffe@bd.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-to-invest-35-million-in-nebraska-facility-to-expand-prefilled-flush-syringe-manufacturing-to-support-us-health-care-302520334.html

SOURCE BD (Becton, Dickinson and Company)

FAQ

What is BD's new investment in Nebraska manufacturing facility?

BD is investing $35 million in its Columbus, Nebraska facility to expand prefilled flush syringe manufacturing capacity and add approximately 50 new jobs.

How many additional jobs will BD (NYSE: BDX) create with this expansion?

The expansion will create approximately 50 new jobs at BD's Columbus, Nebraska facility.

What is BD's total planned investment in U.S. manufacturing over the next five years?

BD plans to invest $2.5 billion in U.S. manufacturing capacity over the next five years to strengthen healthcare infrastructure and supply chain resilience.

How much has BD increased its PosiFlush production in recent years?

Over the past three years, BD has increased U.S. production by more than 750 million units, including a 10% increase this year alone.

How many U.S. manufacturing facilities does BD operate?

BD operates more than 30 manufacturing and distribution facilities across 17 states and Puerto Rico, employing over 10,000 people.